✦ LIBER ✦

Fever following administration of two inactivated influenza vaccines—A survey of parents of New Zealand infants and children 5 years of age and under

✍ Scribed by Helen Petousis-Harris; Tracey Poole; Robert Booy; Nikki Turner

Book ID: 116963536
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 173 KB
Volume: 29
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2011.02.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Serum and mucosal immunologic responses

Serum and mucosal immunologic responses in children following the administration of a new inactivated intranasal anti-influenza vaccine

✍ Evgenia Greenbaum; Arthur Furst; Alexander Kiderman; Brendon Stewart; Reuven Lev 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract Children are at considerable risk for influenza infection and may constitute the main vector for transmitting the virus to adults in the community. At present, the use of available vaccines in children is limited mainly because of a fear of side effects from the injection. Intranasal im

SAFETY AND IMMUNOGENICITY OF A NEW HAEMO

SAFETY AND IMMUNOGENICITY OF A NEW HAEMOPHILUS INFLUENZAE TYPE b VACCINE IN INFANTS UNDER ONE YEAR OF AGE

✍ KING, S 📂 Article 📅 1981 🏛 The Lancet 🌐 English ⚖ 583 KB

The risk of fever following one dose of

The risk of fever following one dose of trivalent inactivated influenza vaccine in children aged ≥6 months to <36 months: A comparison of published and unpublished studies

✍ Kaczmarek, Marlena C.; Duong, Uyen T.; Ware, Robert S.; Lambert, Stephen B.; Kel 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 549 KB

Long-term (5-year) antibody persistence

Long-term (5-year) antibody persistence following two- and three-dose regimens of a combined hepatitis A and B vaccine in children aged 1–11 years

✍ Helen Marshall; Terry Nolan; Javier Díez Domingo; Lars Rombo; Etienne M. Sokal; 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 415 KB

Evaluation of a probiotics, Bifidobacter

Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age

✍ F. Matsuda; M.I. Chowdhury; A. Saha; T. Asahara; K. Nomoto; A.A. Tarique; T. Ahm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 224 KB

Corrigendum to “Evaluation of a probioti

Corrigendum to “Evaluation of a probiotics, Bifidobacterium breve BBG-01, for enhancement of immunogenicity of an oral inactivated cholera vaccine and safety: A randomized, double-blind, placebo-controlled trial in Bangladeshi children under 5 years of age” [Vaccine 29 (2011) 1855–1858]

✍ F. Matsuda; M.I. Chowdhury; A. Saha; T. Asahara; K. Nomoto; A.A. Tarique; T. Ahm 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 84 KB